ArticleStem cell research & therapy2025
Culturing hypoxia-primed mesenchymal stem cells in xeno- and serum-free conditions facilitates the synthesis of an extracellular matrix-based biologic with augmented therapeutic potential for the treatment of diabetic wounds.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetic wound healing is severely impaired by poor angiogenesis, neuropathy, chronic inflammation, decreased cell proliferation and dysregulated extracellular matrix (ECM) synthesis. Here, we developed a human mesenchymal stem cell (MSC)-derived ECM-based biologic with augmented pro-angiogenic potential, free of any xeno- and serum-free components, aimed at treating diabetic wounds. Hypoxia-primed MSCs, cultured in chemically defined medium, synthesized a secretome enriched in pro-angiogenic factors. This secretome was aggregated and co-precipitated by a heparan sulfate mimetic, dextran sulfate (DxS), into the pericellular space. MSCs assembled the deposited secretome components into an insoluble ECM, which upon decellularization was processed into MIcroParticles of SOlidified Secretome (MIPSOS), an ECM-DxS composite biologic. This formulation of MIPSOS demonstrated augmented pro-angiogenic bioactivity in vitro and in vivo and accelerated revascularization, re-epithelization and wound closure by almost doubling wound closure rate, and outperforming GraftJacket
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.